Clinical Trial Generates Promising Results for Obinutuzumab in Patients with Lupus Nephritis

ReachMD Healthcare Image


Clinical Trial Generates Promising Results for Obinutuzumab in Patients with Lupus Nephritis

Clinical Trial Generates Promising Results for Obinutuzumab in Patients with Lupus Nephritis

Lupus nephritis is a severe complication of systemic lupus erythematosus (SLE) that affects the kidneys. It is characterized by inflammation and damage to the kidney tissues, leading to impaired kidney function. Current treatment options for lupus nephritis often involve immunosuppressive drugs, but they are not always effective and can have significant side effects.

However, a recent clinical trial has shown promising results for a new treatment option called obinutuzumab. Obinutuzumab is a monoclonal antibody that targets a specific protein called CD20, which is found on the surface of certain immune cells.

The clinical trial involved a group of patients with lupus nephritis who were randomly assigned to receive either obinutuzumab or a placebo in addition to standard therapy. The results showed that patients who received obinutuzumab had a significantly higher rate of complete renal response compared to those who received the placebo.

Complete renal response is defined as a reduction in proteinuria (excessive protein in the urine) to normal levels, along with improved kidney function. This outcome is crucial in lupus nephritis as it indicates a reduction in inflammation and damage to the kidneys.

Furthermore, the trial also demonstrated that obinutuzumab was generally well-tolerated by the patients, with no significant increase in adverse events compared to the placebo group. This is an important finding as it suggests that obinutuzumab could be a safe and effective treatment option for lupus nephritis.

These promising results have sparked hope among the medical community and patients with lupus nephritis. Obinutuzumab could potentially offer a more targeted and effective treatment option, with fewer side effects compared to current therapies.

However, further research and larger clinical trials are needed to confirm these findings and establish the long-term safety and efficacy of obinutuzumab in treating lupus nephritis. It is also important to determine the optimal dosage and treatment duration for maximum benefit.

In conclusion, the clinical trial results for obinutuzumab in patients with lupus nephritis are highly encouraging. This new treatment option has shown promising results in achieving complete renal response and appears to be well-tolerated. With further research and validation, obinutuzumab could potentially revolutionize the management of lupus nephritis and improve the quality of life for patients suffering from this debilitating condition.

© Article Copyright 1999-2023

Life Technology™


If you would like to republish the content of this or any other article from for commercial purposes visit

Life Technology™ News Content Syndication Licence

. If you would like to republish the content of this or any other article from for non commercial purposes visit

Copyright And Royalty Free RSS Feeds For Commercial And Non Commercial Use


If you would like for us to publish your article at visit

Publish Your Article At Life Technology™

. If you would like to advertise here and on all 100,000+ pages of visit

Advertise At Life Technology™

. For corporate sponsorship of visit

Corporate Sponsorship


Since 1999 Life Technology™ has published medical science and technology news content totally free of charge. Because we do not charge a subscription fee we would kindly request that you

Make A Donation To Life Technology™

and please, do share this article with your coworkers, friends, family and favorite social media platform.

  • Using cardiac MRI to investigate cause of cardiomyopathy in coronary artery disease
  • Adolescent and young adult sex workers more likely to experience muscle dysmorphia, find study
  • Spread of drug resistant bacteria linked to patient hand contamination and antibiotic use within nursing homes
  • Antibodies to cow's milk linked to increased risk of cardiovascular death
  • New approach to pancreatic cancer treatment expands therapeutic possibilities, shows promise for increased survival
  • Study finds tapering TNF inhibitors increases flares, lowers Boolean remission rates for RA patients in remission
  • Research links sleep apnea to increased risk of atrial fibrillation
  • Study shows stem cell transplant significantly improves outcomes in refractory juvenile systemic sclerosis
  • High-precision superimposition of X-ray fluoroscopic images and 3D CT data
  • New landscape map highlights Michigan counties affected hardest by opioid epidemic
  • Getting adequate vitamin D in the fall and winter
  • Physical fitness since childhood associated with cerebellar volume in adolescence: Study
  • Clinical trial targets fetal heart disorder detection in pregnant women
  • More than half of COVID-19 patients have post-disease syndrome, finds research
  • Report shows most deaf people with cochlear implants satisfied, but more follow-up supports needed
  • New doctors should pass a prescribing skills test before they qualify to improve safety for patients, says study
  • Top ten steps to improve in-hospital cardiac arrest outcomes and care identified
  • New research offers hope for reduced muscle wastage in cancer patients
  • A comprehensive evaluation of spontaneous pelvic organ prolapse in non-human primates as a model for human studies
  • Racial, ethnic disparities in long-term care remain among older adults despite passage of Affordable Care Act: Study
  • Telemedicine treatment for HCV in people with opioid use disorder more than twice as successful as offsite referral
  • Norovirus: What to know and how to avoid it
  • Lab builds mock MRI machine to prep kids for studies
  • New report reveals autistic adults' social media experiences
  • Research suggests prenatal exposure to cannabis increases diabetes risk in offspring
  • Q&A: Fertility considerations in cancer treatment, preserving hope for the future
  • How much vision loss impairs your driving? New study has answers
  • Earlier onset of atrial fibrillation linked to risk of developing all-cause dementia
  • Majority of workers at America's nursing homes unvaccinated against flu, COVID
  • Considerable shortages of minoxidil recorded in greater DC area
  • About 1 in 6 older Australians experiences elder abuse. Here are the reasons they don't get help
  • Q&A: Treatment for a parastomal hernia
  • Babies are contracting salmonella after handling pet food, FDA warns
  • Researchers reveal sex-dimorphic functions of intestinal MCT1 in regulating metabolic homeostasis
  • Deciphering the secrets of spinal cord regeneration protein by protein
  • New tumor marker can detect gastric cancer with nearly 90% accuracy
  • Where and how you sit matters when getting blood pressure taken at the doctor's office
  • Australia is in a new COVID wave. What can be expected this time?
  • Perimenopause usually begins in your 40s: How do you know if it has started?
  • How autistic parents feel about breastfeeding and the support they receive
  • Liver cells age differently depending on where they are in the organ, study shows
  • Therapy resistance in multiple myeloma: Molecular analyses of individual cancer cells reveal new mechanisms
  • Scientists identify crucial role of protein neuregulin-1 in heart development
  • Relieving stress in insulin-producing cells protects against type 1 diabetes
  • Clinical trial generates promising results for obinutuzumab in patients with lupus nephritis
  • Study identifies countries vulnerable to extensively drug-resistant typhoid
  • Novo Nordisk invests $6 bn to boost anti-obesity drug output
  • US approves first vaccine against chikungunya virus
  • Lack of friend or family visits is associated with increased risk of dying
  • WHO updates its guidance on treatments for COVID-19
  • Life Technology™ Medical NewsFeedburnerGoogleRSSLife Technology™ Science NewsFeedburnerGoogleRSSLife Technology™ Technology NewsFeedburnerGoogleRSS

    Facebook Comments


    We’re glad to see you’re enjoying Rheumatology Academy…
    but how about a more personalized experience?

    Register for free